Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is poised for long-term success due to its promising pipeline of selective oral immunology therapies targeting various chronic inflammatory and autoimmune diseases. With positive results from the Phase 2 EMPhASIS trial, including a significant reduction in combined unique active (CUA) MRI lesions in patients with relapsing-remitting MS versus placebo, the company's Phase 3 ENSURE program in RMS is positioned for success. The company's strong focus on reducing clinical relapse and confirmed disability progression, combined with its differentiated dual-mechanism approach, makes it a promising investment opportunity in the life sciences sector.

Bears say

Immunic is a clinical-stage biopharmaceutical company that focuses on developing therapies for chronic inflammatory and autoimmune diseases. However, its lead product candidate, vidofludimus calcium, may face challenges in gaining market traction due to its niche targeting of neuroprotection and relapse prevention. Additionally, the recent reverse stock split, while addressing compliance and providing necessary capital, may signal underlying weakness in investor demand and introduce dilution risks.

Immunic Inc (IMUX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.